Ali Al-Asmari, MD د. علي الأسمري

Had the opportunity to present at the CRA (Canadian Rheumatology Association) Annual Scientific Meeting 2026.. Grateful for the experience..

This is largest international cohort of #monogenic #lupus so far (100 children, multi-country). Early onset (median aprox. 2 years), high consanguinity, and significant disease burden. C1Q and DNASE1L3 accounted for 50% of cases, with clear genotype–phenotype separation: - C1Q: more neuro + recurrent infections - DNASE1L3: milder course Clinical picture is broad, but mucocutaneous, MSK, and neuro involvement dominate. Infections were common (aprox. 36%) and not trivial. Mortality reached 16%..!! #SLE

رب اجعل هذا البلد آمناً🤲🏼 🇸🇦

وحدة وتلاحم من 299 عام. #يوم_التأسيس

When lupus starts early and joints erode (Rhupus like), pause…!! That is not typical SLE, think monogenic lupus…!! #Monogenic #Lupus #SLE

In #Lupus #Nephritis، delay costs nephrons.. Time is nephron, & nephron is time..!!

Glad to share this work on #monogenic #lupus , and grateful to work with KFSHRC staff Prof. Sulaiman Al-Mayouf and Dr. AlSaleem Most of these patients had long journeys with frequent immunosuppressive therapies.. variable but meaningful responses were observed after starting #baricitinib

Who knows lupus, knows medicine..

Low-grade proteinuria in lupus nephritis is (not benign) In a 239-patient biopsy proven cohort (156 week follow up), baseline UPro <1 g/day did (not) predict better response or better long-term eGFR outcomes. Chronic damage, especially glomerulosclerosis, was the key prognostic signal (esp in relapsing LN).. pubmed.ncbi.nlm.nih.gov/41312658/ Nov 28, 2025, Arthritis Rheumatology

PRKCD deficiency connects autoimmunity and infection: a fatal form of lupus and susceptibility to BCGitis in affected children.

Using a target trial emulation, Grace Haeun Lee showed that belimumab was associated with reduced risk of all cause mortality compared with AZA, MTX, and MMF #ACR2025

It’s fascinating to see lupus being approached by organ involvement, rather than one uniform pathway. This concept has appeared in scattered papers over the years.. but it’s finally being shaped more clearly and clinically.. I think, we should start doing the same for monogenic lupus, but with pathway or gene targeted initial treatments, instead of starting with the traditional SLE medications by default..

Early IL-1 inhibitor introduction in patients with Still disease may lead to higher rates of clinical inactive disease and GC discontinuation compared with late treatment, supporting a window of opportunity in Still disease management ACROR doi.org/10.1002/acr2.7…

T-cell engagers are emerging as a next generation therapy in refractory SLE.. By coupling CD3 on T cells to B-cell or plasma-cell targets (CD19, CD20, BCMA), agents like Teclistamab, A-319, and CLN-978 induce precise immune reset… Early data show deep B-cell depletion with manageable safety.. potentially bridging biologics and CAR-T. (( Image borrowed from Lupus Therapeutics Webinar )) #SLE #Immunotherapy #TCellEngagers #Autoimmunity #Rheumatology #TCE

Classically, kidney injury in Lupus Nephritis was attributed to the canonical NLRP3–Caspase-1 inflammasome. What’s new: recent human & animal data link non-canonical pyroptosis (Caspase-4/5/11–GSDMD in macrophages) directly to LN activity & chronicity. Pathway itself is known in infection biology and other types if inflammation.. but its role in LN pathogenesis & as a therapeutic target is emerging. interesting..!! #Lupus #Nephritis #Immunology

دوام العز لوطني.. السعودية.. وطنٌ إذا نظرت في أفقه أيقنت أن الفخر لا يشيخ..

Does your child struggle with the fear of needles? 💉 Join our free webinar! Parents, caregivers & health-care professionals will learn evidence-based strategies to help children feel supported when needles are a necessary part of their care Register: us02web.zoom.us/meeting/regist…

Thrilled to co-chair the “Childhood Lupus” session at APLAR2025 congress and speak on “Monogenic Lupus”!

📝 The 2025 ACR guidelines published in @ACRheum recommend minimizing glucocorticoid exposure in patients with stable SLE by tapering prednisone from ≥5 mg/day to ≤5 mg/day within 6 months. More news: lupushub.com #lupus #SLE #MedNews #MedEd